Increased CD80+ B cells in active multiple sclerosis and reversal by interferon β-1b therapy

Journal of Clinical Investigation

Volumn 99, Issue 11, 1997, Pages 2664-2671

  Genç, Kürşad ^a,b   Dona, Daniel L ^a   Reder, Anthony T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Dokuz Eylul School of Medicine   (Turkey)

Author keywords

Blymphocyte; CD80; CD86; Interferon ; Multiple sclerosis

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; INTERFERON BETA SERINE; INTERLEUKIN 2 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ADULT; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; AUTOLOGOUS MIXED LYMPHOCYTE REACTION; B LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MALE; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PRIORITY JOURNAL; RECEPTOR BINDING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0030973198     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119455     Document Type: Article

References (56)

1. Chen, C., and N. Nabavi. 1994. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity. 1: 147-154.
2. Flores Villanueva, P.O., H. Reiser, and M.J. Stadecker. 1994. Regulation of T helper cell responses in experimental murine schistosomiasis by IL-10. J. Immunol. 153:5190-5199.
3. Bluestone, J.A. 1995. New perspectives of CD28-B7-mediated T cell costimulation. Immunity. 2:555-559.
4. Verweij, C.L., M. Geerts, and L.A. Aarden. 1991. Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-κB-like response element. J. Biol. Chem. 166:14179-14182.
5. June, C.H., J.A. Bluestone, L.M. Nadler, and C.B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today. 15:321-331.
6. Schwartz, R.H. 1996. Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med. 184:1-8.
7. Lenschow, D.J., A.I. Sperling, M.P. Cooke, G. Freeman, L. Rhee, D.C. Decker, G. Gray, L.M. Nadler, C.C. Goodnow, and J.A. Bluestone. 1994. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J. Immunol. 153:1990-1997.
8. Kuchroo, V.K., M.P. Das, J.A. Brown, A.M. Ranger, S.S. Zamvil, R.A. Sobel, H.L. Weiner, N. Nabavi, and L.H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:707-718.
9. Freeman, G.J., V.A. Boussiotis, A. Anumanthan, G.M. Bernstein, X.-Y. Ke, P.D. Rennert, G.S. Gray, J.G. Gribben, and L.M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 2:523-532.
10. Kennedy, M.K., D.S. Torrance, K.S. Picha, and K.M. Mohler. 1992. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:2496-2505.
11. Khoury, S.J., W.W. Hancock, and H.L. Weiner. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1355-1364.
12. Arnason, B.G.W., and A.T. Reder. 1994. Interferons and multiple sclerosis. Clin. Neuropharmacol. 17:495-547.
13. Cross, A.H., T.J. Girard, K.S. Giacoletto, R.J. Evans, R.M. Keeling, R.F. Lin, J.L. Trotter, and R.W. Karr. 1995. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95:2783-2789.
14. Perrin, P.J., D. Scott, L. Quigley, P.S. Albert, O. Feder, G.S. Gray, R. Abe, C.H. June, and M.K. Racke. 1995. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol. 154:1481-1490.
15. Khoury, S.J., E. Akalin, A. Chandraker, L.A. Turka, P.S. Linsley, M.H. Sayegh, and W.W. Hancock. 1995. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155:4521-4524.
16. Miller, S.D., C.L. Vanderlugt, D.J. Lenschow, J.G. Pie. N.J. Karandikar, M.C. Dal Canto, and J.A. Bluestone. 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity. 3:739-745.
17. De Simone, R., A. Giampaolo, B. Giometto, P. Gallo, G. Levi, C. Peschle, and F. Aloisi. 1995. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J. Neuropathol. & Exp. Neurol. 54:175-187.
18. Williams, K., E. Ulvestad, and J.P. Antel. 1994. B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. Eur. J. Immunol. 24: 3031-3037.
19. Windhagen, A., J. Newcombe, F. Dangond, C. Strand, M.N. Woodroofe, M.L. Cuzner, and D.A. Hafler. 1995. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182:1985-1996.
20. Reder, A.T., and B.G.W. Arnason. 1985. Immunology of multiple sclerosis. In Handbook of Clinical Neurology: Demyelinating Diseases. P.J. Vinken, G.W. Bruyn, H.L. Klawans, and J.C. Koetsiers, editors. Elsevier Science Publishers. Amsterdam. 337-395.
21. Kurtzke, J.F. 1983. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1444-1452.
22. Harshbarger, T.R. 1971. Introductory Statistics: A Decision Map. The Macmillan Company, New York. 558 pp.
23. Guerder, S., J. Meyerhoff, and R. Flavell. 1994. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity. 1:155-166.
24. Antel, J.P., B.G.W. Arnason, and M.E. Medof. 1978. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann. Neurol. 5:338-342.
25. Reder, A.T., J.P. Antel, J.J. Oger, T.A. McFarland, M. Rosenkoetter, and B.G. Arnason. 1984. Low T8 antigen density on lymphocytes in active multiple sclerosis. Ann. Neurol. 16:242-249.
26. Sibley, W.A., C.R. Bamford, and K. Clark. 1985. Clinical viral infections and multiple sclerosis. Lancet. i:1313-1315.
27. Panitch, H.S. 1994. Influence of infection on exacerbations of multiple sclerosis. Ann. Neurol. 36:S25-S28.
28. Schiffenbauer, J., H.M. Johnson, E. Butfiloski, L. Wegrzyn, and J.M. Soos. 1993. Staphylococcal enteroloxins reactivate experimental allergic encephalomyelitis. Proc. Aatl. Acad. Sci. USA. 90:8543-8546.
29. Beck, J., P. Rondot, L. Catinot, E. Falcoff, H. Kirchner, and J. Wietzerbin. 1988. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol. Scand. 78:318-323.
30. Rieckmann, P., M. Albrecht, B. Kitze, T. Weber, H. Tumani, A. Broocks, W. Lüer, and S. Poser. 1994. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 44:1523-1526.
31. Rieckmann, P., M. Albrecht, B. Kitze, T. Weber, H. Tumani, A. Broocks, W. Lüer, A. Helwig, and S. Poser. 1995. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 37:82-88.
32. Byskosh, P.V., and A.T. Reder. 1995. IFN β-1b effects on cytokine mRNA in multiple sclerosis. Ann. Neurol. 38:340a.
33. Birnbaum, G., and L. Kotilinek. 1981. Autologous lymphocyte proliferation in multiple sclerosis and the effect of intravenous ACTH. Ann. Neurol. 9: 439-446.
34. Hofman, F.M., R.I. von Hanwehr, C.A. Dinarello, S.B. Mizel, D. Hinton, and J.E. Merrill. 1986. Immunoregulatory molecules and IL2 receptors identified in multiple sclerosis brain. J. Immunol. 136:3239-3245.
35. Cuzner, M.L., G.M. Hayes, J. Newcombe, and M.N. Woodroofe. 1988. The nature of inflammatory components during demyelination in multiple sclerosis. J. Neuroimmunol. 20:203-209.
36. Freudenthal, P.S., and R.M. Steinman. 1990. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc. Natl. Acad. Sci. USA. 87:7698-7702.
37. The IFN-Beta Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43: 662-667.
38. 1, affect monokine secretion: relevance to monocyte activation in multiple sclerosis. Cell. Immunol. 157:428-438.
39. Rudick, R.A., R.M. Ransohoff, R. Peppler, S.V. Medendorp, P. Lehmann, and J. Alam. 1996. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 40:618-627.
40. Ding, L., P.S. Linsley, L.-Y. Huang, R.N. Germain, and E.M. Shevach. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 151:1224-1234.
41. Larsen, C.P., S.C. Ritchie. R. Henrix, P.S. Linsley, K.S. Hathcock, R.J. Modes, R.P. Lowry, and T.C. Pearson. 1994. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol. 152:5208.
42. Byskosh, P.V. , and A.T. Reder. 1996. Interferon-β effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Multiple Sclerosis. 1:262-269.
43. Panitch, H.S., R.L. Hirsch, J. Schindler, and K.P. Johnson. 1987. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 37:1097-1102.
44. Noronha, A., A. Toscas, and M.A. Jensen. 1993. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J. Neuroimmunol. 46:145-154.
45. Revel, M., J. Chebath, M. Mangelus, S. Harroch, and G.A. Moviglia. 1995. Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Multiple Sclerosis. 1:S5-S11.
46. Lombardi, G., S. Sidhu, R. Batchelor, and R. Lechler. 1994. Anergic T cells as suppressor cells in vitro. Science (Wash. DC). 264:1587-1589.
47. Brocke, S., K. Gijbels, M. Allegretta, I. Ferber, C. Piercy, T. Blankenstein, R. Martin, U. Utz, N. Karin, D. Mitchell, et al. 1996. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature (Lond.). 379:343-346.
48. Rudick, R.A., C.S. Carpenter, D.L. Cookfair, V.K. Tuohy, and R.M. Ransohoff. 1993. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology. 43:2080-2087.
49. Lenschow, D.J., S.C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K.C. Herold, and J.A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145-1155.
50. Finck, B.K., P.S. Linsley, and D. Wofsy. 1994. Treatment of murine lupus with CTLA4Ig. Science (Wash. DC). 265:1225-1227.
51. Lu, P., X. di Zhou, S.-J. Chen, M. Moorman, A. Schoneveld, S. Morris, F.D. Finkelman, P. Linsley, E. Claassen, and W.C. Gause. 1995. Requirement Of CTLA-4 counter receptors for 1L-4 but not IL-10 elevations during a primary systemic in vivo immune response. J. Immunol. 154:1078-1087.
52. Rott, O., B. Fleischer, and E. Cash. 1994. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24:1434-1440.
53. Skias, D.D., and A.T. Reder. 1995. IL-10 inhibits EAE. Neurology. 45(Suppl. 4):349a.
54. Roth, R., T. Nakamura, and M.J. Mamula. 1996. B7 costimulation and autoantigen specificity enable B cells to activate autoreactive T cells. J. lmmunol. 157:2924-2931.
55. Bashir, R.M. , and J.N. Whitaker. 1980. Metabolism of a peptide of human myelin basic protein in the rabbit. Neurology. 30:1184-1192.
56. Correale, J., W. Gilmore, J. Lopez, S.Q. Li, M. McMillan, and L.P. Weiner. 1996. Defective post-thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis. Nat. Med. 2:1354-1360.